ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "5ad62b65-ef80-4e9f-9752-f92fb7d8f00a"}, "_deposit": {"id": "21089", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "21089"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:00021089", "sets": ["1807"]}, "item_9_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2015-11", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "4", "bibliographicPageEnd": "646", "bibliographicPageStart": "637", "bibliographicVolumeNumber": "77", "bibliographic_titles": [{"bibliographic_title": "Nagoya Journal of Medical Science"}]}]}, "item_9_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "The purposes of this study on prostate cancer are to demonstrate the time course of International Prostate Symptom Score (IPSS) after intensity-modulated radiation therapy (IMRT) combined with androgen deprivation therapy (ADT) and to examine the factor associated with the IPSS change. This study included 216 patients treated with IMRT between 2006 and 2010. Patients were evaluated in three groups according to baseline IPSS as defined by the American Urological Association classification, where IPSSs of 0 to 7, 8 to 19, and 20 to 35 represent mild (n = 124), moderate (n = 70), and severe (n = 22) symptom groups, respectively. The average IPSSs ± standard deviation at baseline vs. those at 24 months after IMRT were 3.5 ± 2.1 vs. 5.1 ± 3.6 in the mild group (P \u003c 0.001), 12.6 ± 3.4 vs. 10.0 ± 6.0 in the moderate group (P = 0.0015), and 23.8 ± 2.9 vs. 14.4 ± 9.1 in the severe group (P \u003c 0.001). Among factors of patient and treatment characteristics, age, IPSS classification, pretreatment GU medications, and positive biopsy rates were associated with the IPSS difference between baseline and 24 months (P = 0.023, \u003c 0.001, 0.044, and 0.028, respectively). In conclusion, patients with moderate to severe urinary symptoms can exhibit improvement in urinary function after IMRT, whereas patients with mild symptoms may have slightly worsened functions. Age, baseline IPSS, GU medications, and tumor burden in the prostate can have an effect on the IPSS changes.", "subitem_description_type": "Abstract"}]}, "item_9_identifier_60": {"attribute_name": "URI", "attribute_value_mlt": [{"subitem_identifier_type": "URI", "subitem_identifier_uri": "http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/774.html"}, {"subitem_identifier_type": "HDL", "subitem_identifier_uri": "http://hdl.handle.net/2237/23228"}]}, "item_9_identifier_registration": {"attribute_name": "ID登録", "attribute_value_mlt": [{"subitem_identifier_reg_text": "10.18999/nagjms.77.4.637", "subitem_identifier_reg_type": "JaLC"}]}, "item_9_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Nagoya University Graduate School of Medicine, School of Medicine"}]}, "item_9_select_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_9_source_id_7": {"attribute_name": "ISSN(print)", "attribute_value_mlt": [{"subitem_source_identifier": "0027-7622", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Tomita, Natsuo"}], "nameIdentifiers": [{"nameIdentifier": "60991", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Oze, Isao"}], "nameIdentifiers": [{"nameIdentifier": "60992", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shimizu, Hidetoshi"}], "nameIdentifiers": [{"nameIdentifier": "60993", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yoshida, Maiko"}], "nameIdentifiers": [{"nameIdentifier": "60994", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kimura, Kana"}], "nameIdentifiers": [{"nameIdentifier": "60995", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Takehana, Keiichi"}], "nameIdentifiers": [{"nameIdentifier": "60996", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shimizu, Arisa"}], "nameIdentifiers": [{"nameIdentifier": "60997", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Makita, Chiyoko"}], "nameIdentifiers": [{"nameIdentifier": "60998", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tachibana, Hiroyuki"}], "nameIdentifiers": [{"nameIdentifier": "60999", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kodaira, Takeshi"}], "nameIdentifiers": [{"nameIdentifier": "61000", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Soga, Norihito"}], "nameIdentifiers": [{"nameIdentifier": "61001", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ogura, Yuji"}], "nameIdentifiers": [{"nameIdentifier": "61002", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hayashi, Norio"}], "nameIdentifiers": [{"nameIdentifier": "61003", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2018-02-21"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "19_Tomita.pdf", "filesize": [{"value": "220.4 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 220400.0, "url": {"label": "19_Tomita.pdf", "url": "https://nagoya.repo.nii.ac.jp/record/21089/files/19_Tomita.pdf"}, "version_id": "3a1a0d50-a31f-4c6e-9930-5836da894054"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "IPSS", "subitem_subject_scheme": "Other"}, {"subitem_subject": "prostate cancer", "subitem_subject_scheme": "Other"}, {"subitem_subject": "genitourinary toxicity", "subitem_subject_scheme": "Other"}, {"subitem_subject": "IMRT", "subitem_subject_scheme": "Other"}, {"subitem_subject": "ADT", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "International prostate symptom score (IPSS) change and changing factor in intensity-modulated radiotherapy combined with androgen deprivation therapy for prostate cancer", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "International prostate symptom score (IPSS) change and changing factor in intensity-modulated radiotherapy combined with androgen deprivation therapy for prostate cancer"}]}, "item_type_id": "9", "owner": "1", "path": ["1807"], "permalink_uri": "https://doi.org/10.18999/nagjms.77.4.637", "pubdate": {"attribute_name": "公開日", "attribute_value": "2015-11-24"}, "publish_date": "2015-11-24", "publish_status": "0", "recid": "21089", "relation": {}, "relation_version_is_last": true, "title": ["International prostate symptom score (IPSS) change and changing factor in intensity-modulated radiotherapy combined with androgen deprivation therapy for prostate cancer"], "weko_shared_id": null}
  1. C100 医学部/医学系研究科
  2. C100b 紀要
  3. Nagoya journal of medical science
  4. 77(4)

International prostate symptom score (IPSS) change and changing factor in intensity-modulated radiotherapy combined with androgen deprivation therapy for prostate cancer

https://doi.org/10.18999/nagjms.77.4.637
https://doi.org/10.18999/nagjms.77.4.637
77b7cafe-bb88-4228-ac4e-19fd4c93aeed
名前 / ファイル ライセンス アクション
19_Tomita.pdf 19_Tomita.pdf (220.4 kB)
Item type 紀要論文 / Departmental Bulletin Paper(1)
公開日 2015-11-24
タイトル
タイトル International prostate symptom score (IPSS) change and changing factor in intensity-modulated radiotherapy combined with androgen deprivation therapy for prostate cancer
著者 Tomita, Natsuo

× Tomita, Natsuo

WEKO 60991

Tomita, Natsuo

Search repository
Oze, Isao

× Oze, Isao

WEKO 60992

Oze, Isao

Search repository
Shimizu, Hidetoshi

× Shimizu, Hidetoshi

WEKO 60993

Shimizu, Hidetoshi

Search repository
Yoshida, Maiko

× Yoshida, Maiko

WEKO 60994

Yoshida, Maiko

Search repository
Kimura, Kana

× Kimura, Kana

WEKO 60995

Kimura, Kana

Search repository
Takehana, Keiichi

× Takehana, Keiichi

WEKO 60996

Takehana, Keiichi

Search repository
Shimizu, Arisa

× Shimizu, Arisa

WEKO 60997

Shimizu, Arisa

Search repository
Makita, Chiyoko

× Makita, Chiyoko

WEKO 60998

Makita, Chiyoko

Search repository
Tachibana, Hiroyuki

× Tachibana, Hiroyuki

WEKO 60999

Tachibana, Hiroyuki

Search repository
Kodaira, Takeshi

× Kodaira, Takeshi

WEKO 61000

Kodaira, Takeshi

Search repository
Soga, Norihito

× Soga, Norihito

WEKO 61001

Soga, Norihito

Search repository
Ogura, Yuji

× Ogura, Yuji

WEKO 61002

Ogura, Yuji

Search repository
Hayashi, Norio

× Hayashi, Norio

WEKO 61003

Hayashi, Norio

Search repository
キーワード
主題Scheme Other
主題 IPSS
キーワード
主題Scheme Other
主題 prostate cancer
キーワード
主題Scheme Other
主題 genitourinary toxicity
キーワード
主題Scheme Other
主題 IMRT
キーワード
主題Scheme Other
主題 ADT
抄録
内容記述 The purposes of this study on prostate cancer are to demonstrate the time course of International Prostate Symptom Score (IPSS) after intensity-modulated radiation therapy (IMRT) combined with androgen deprivation therapy (ADT) and to examine the factor associated with the IPSS change. This study included 216 patients treated with IMRT between 2006 and 2010. Patients were evaluated in three groups according to baseline IPSS as defined by the American Urological Association classification, where IPSSs of 0 to 7, 8 to 19, and 20 to 35 represent mild (n = 124), moderate (n = 70), and severe (n = 22) symptom groups, respectively. The average IPSSs ± standard deviation at baseline vs. those at 24 months after IMRT were 3.5 ± 2.1 vs. 5.1 ± 3.6 in the mild group (P < 0.001), 12.6 ± 3.4 vs. 10.0 ± 6.0 in the moderate group (P = 0.0015), and 23.8 ± 2.9 vs. 14.4 ± 9.1 in the severe group (P < 0.001). Among factors of patient and treatment characteristics, age, IPSS classification, pretreatment GU medications, and positive biopsy rates were associated with the IPSS difference between baseline and 24 months (P = 0.023, < 0.001, 0.044, and 0.028, respectively). In conclusion, patients with moderate to severe urinary symptoms can exhibit improvement in urinary function after IMRT, whereas patients with mild symptoms may have slightly worsened functions. Age, baseline IPSS, GU medications, and tumor burden in the prostate can have an effect on the IPSS changes.
内容記述タイプ Abstract
出版者
出版者 Nagoya University Graduate School of Medicine, School of Medicine
言語
言語 eng
資源タイプ
資源 http://purl.org/coar/resource_type/c_6501
タイプ departmental bulletin paper
ID登録
ID登録 10.18999/nagjms.77.4.637
ID登録タイプ JaLC
ISSN(print)
収録物識別子タイプ ISSN
収録物識別子 0027-7622
書誌情報 Nagoya Journal of Medical Science

巻 77, 号 4, p. 637-646, 発行日 2015-11
著者版フラグ
値 publisher
URI
識別子 http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/774.html
識別子タイプ URI
URI
識別子 http://hdl.handle.net/2237/23228
識別子タイプ HDL
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 15:32:09.675121
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3